Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation for Multiple Myeloma: Results from the Japan Myeloma Study Group

  • Chihiro Shimazaki
  • Hiroshi Fujii
  • Takashi Yoshida
  • Takaaki Chou
  • Miki Nishimura
  • Hideki Asaoku
  • Shuichi Miyawaki
  • Akihiro Ishii
  • Tadao Ishida
  • Masafumi Taniwaki
  • Shinsuke Iida
  • Toshiyuki Takagi
  • Kiyoshi Takatsuki
Progress Hematology

DOI: 10.1532/IJH97.04174

Cite this article as:
Shimazaki, C., Fujii, H., Yoshida, T. et al. Int J Hematol (2005) 81: 342. doi:10.1532/IJH97.04174

Abstract

We conducted a retrospective survey of multiple myeloma (MM) patients who underwent reduced-intensity conditioning allogeneic stem cell transplantation (RIST) at 11 hospitals participating in the Japan Myeloma Study Group. Forty-five patients (median age, 53 years) were included in this study. The conditioning regimen consisted of a fludarabine-based regimen in 24 patients and a regimen based on total body irradiation (1–2 Gy) in 18 patients. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and tacrolimus in 28 and 17 patients, respectively. All patients showed myeloid engraftment. Complete chimerism was obtained in 42 patients. Grade II to IV acute GVHD developed in 28 (65%) of 43 patients evaluated, and chronic GVHD developed in 31 (76%) of 41 patients. Early death before day 100 was observed in 4 patients (8.8%). A complete response (CR) was obtained in 12 patients. The factors affecting overall survival were severe acute GVHD and the response after RIST. To date, 18 patients are alive, with 9 patients remaining in CR at a median follow-up of 25 months. The overall and progression-free survival rates at 3 years were 38.5% and 18.8%, respectively. These observations suggest that RIST is feasible with reliable donor engraftment and relatively low transplantation-related mortality in Japanese MM patients.

Key words

Multiple myeloma Reduced-intensity conditioning stem cell transplantation (RIST) Japan Myeloma Study Group (JMSG) 

Copyright information

© The Japanese Society of Hematology 2005

Authors and Affiliations

  • Chihiro Shimazaki
    • 1
  • Hiroshi Fujii
    • 2
  • Takashi Yoshida
    • 3
  • Takaaki Chou
    • 4
  • Miki Nishimura
    • 5
  • Hideki Asaoku
    • 6
  • Shuichi Miyawaki
    • 7
  • Akihiro Ishii
    • 8
  • Tadao Ishida
    • 9
  • Masafumi Taniwaki
    • 10
  • Shinsuke Iida
    • 11
  • Toshiyuki Takagi
    • 12
  • Kiyoshi Takatsuki
    • 12
  1. 1.Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of MedicineKamigyoku, KyotoJapan
  2. 2.Department of HematologyKyoto First Red Cross HospitalKyoto
  3. 3.Department of MedicineToyama Prefectural Central HospitalToyama
  4. 4.Department of MedicineNiigata Cancer Center HospitalNiigata
  5. 5.Second Department of MedicineChiba University School of MedicineChiba
  6. 6.Fourth Department of Internal MedicineHiroshima Red Cross Hospital and Atomic-Bomb Survivors HospitalHiroshima
  7. 7.Department of HematologySaiseikai Maehashi HospitalMaehashi
  8. 8.Division of Hematology and OncologyChiba Cancer Center HospitalChiba
  9. 9.First Department of Internal MedicineSapporo Medical UniversitySapporo
  10. 10.Department of Molecular Genetics and Laboratory MedicineKyoto Prefectural University of MedicineKyoto
  11. 11.Department of Hematology and Collagen DiseaseNagoya City University HospitalNagoya
  12. 12.Japan Myeloma Study GroupJapan